Abstract: Modafinil in obstructive sleep apnea-hypopnea syndrome

Modafinil in obstructive sleep apnea-hypopnea syndrome
: a pilot study in 6 patients

Arnulf I, Homeyer P, Garma L, Whitelaw WA, Derenne JP.

Service de Pneumologie et Laboratoire du Sommeil,
Hopital Pitie-Salpetriere,
Paris, France.
Respiration 1997; 64(2):159-61


We studied the effects of modafinil, a vigilance-enhancing drug, on excessive daytime sleepiness, memory, night sleep and respiration in 6 patients with obstructive sleep apnea-hypopnea syndrome (OSAHS) using a double-blind random cross-over design with 24-hour polysomnography, verbal memory test and a 5-week sleep-wake diary kept by the patients. There were two 2-week treatment periods in which either modafinil or placebo was used; they were separated by a 1-week wash-out period. Our results show that modafinil reduces daytime sleep duration, lengthens the duration of subjective daytime vigilance and improves long-term memory in patients with OSAHS without modifying night sleep and respiration events.